Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Scaling autologous CAR‑T therapy faces manufacturing bottlenecks On September 1, PharmaVoice described the manufacturing challenge of autologous CAR‑T: each patient requires a unique journey from cell collection to treatment. Using Carvykti as an example, the process depends on production, quality control, logistics, and clinic scheduling. Autologous CAR‑T is a cancer cell therapy made from the patient’s own T‑cells, which are engineered, expanded, tested, and returned to the same individual, with each dose undergoing its own cycle. As patient numbers rise, clinics and manufacturers must run many of these cycles in parallel. Cells, factory slots, materials, QC, dose release, delivery, and treatment timing must align for each person; a delay anywhere postpones that patient’s therapy. “When you scale autologous cell therapy, you’re not enlarging a single batch — you’re replicating processes,” said Mike O’Mara, COO of Cellipont Bioservices, a contract cell‑therapy manufacturer. Early on, one experienced team can handle several cycles, but commercial production uses multiple teams simultaneously reproducing the same personal process; manual steps and operator variability then have a stronger impact on quality and timing. Automation and closed‑system processing reduce manual operations and cycle‑to‑cycle differences. The Carvykti network already shows this scale: it is available at 348 sites in 19 countries according to Legend Biotech, and all four of its manufacturing sites are operating. The expanded facility in Raritan, New Jersey, is designed for up to 10,000 patients per year, yet every personalized dose still must pass QC, release, delivery, and clinic scheduling. In June 2025 FDA REMS removal, the agency lifted the special safety program for six approved autologous CAR‑T products, including Carvykti, eliminating the need for separate site certification and updating post‑administration monitoring instructions, thereby simplifying part of the post‑release pathway. In the in vivo CAR‑T approach, a genetic vector delivers instructions that reprogram immune cells inside the patient’s body. June 2025 phase I LB2501 data confirmed that this strategy is being tested in humans, with an ongoing phase I study evaluating whether a single infusion can generate CAR‑T cells in vivo. Such a method could shift much of the external cell‑work to a standardized vector product usable for many patients, although that vector product also requires reliable commercial‑scale manufacturing. _clinical_trials_ 🔗 Read original →